A subgroup analysis of patients with focal segmental glomerulosclerosis demonstrated a trend towards renal benefits with the use of dapagliflozin, although it did not reach statistical significance [ 125 ].
← all excerpts
Pharmacological Nephroprotection in Non-Diabetic Chronic Kidney Disease-Clinical Practice Position Statement of the Polish Society of Nephrology.
2
—
—
The sentences
The study mirrored the spectacular effects of the trial performed earlier in DKD patients, i.e., Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), except for all-cause death, which—although very close to statistical significance—was not reduced by allocation to canagliflozin [ 108 ].